CASI has made surprising progress despite COVID-19. The company reported Evomela sales of $3.37m in Q120, significantly exceeding our expectations. This is the highest single quarter revenue to date (out of three since its August 2019 approval in China). The impact of COVID-19 on sales appears to be low thus far, or at least surpassed by the underlying growth. Moreover, the company continued to advance its development programs CNCT19 and CID-103 at a steady pace.
12 May 2020
CASI Pharmaceuticals - Evomela strong despite COVID-19
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
CASI Pharmaceuticals - Evomela strong despite COVID-19
CASI Pharmaceuticals, Inc. (CASI:NAS) | 0 0 0.0%
- Published:
12 May 2020 -
Author:
Dr Nathaniel Calloway -
Pages:
5
CASI has made surprising progress despite COVID-19. The company reported Evomela sales of $3.37m in Q120, significantly exceeding our expectations. This is the highest single quarter revenue to date (out of three since its August 2019 approval in China). The impact of COVID-19 on sales appears to be low thus far, or at least surpassed by the underlying growth. Moreover, the company continued to advance its development programs CNCT19 and CID-103 at a steady pace.